Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9884421 | Biochemical and Biophysical Research Communications | 2005 | 7 Pages |
Abstract
p53 is a key regulator in cell apoptosis, and cancer cells deficient in p53 expression fail to respond to chemotherapy. Here we show that effective Doxorubicin (DOX)-induced apoptosis is p53-dependent. However, an alternative treatment of DOX/TNF-α/DOX restored sensitivity of p53-deficient cells to DOX-induced apoptosis. Treatment of cells with TNF-α resulted in a decrease of p21 (waf1/cip1/sdi1) expression following second dose of DOX. In previous work, we demonstrated that p21 suppressed DOX-induced apoptosis via its (cyclin-dependent kinase) CDK-binding and CDK-inhibitory activity. Thus, we propose that TNF-α enhances the anti-cancer effect of DOX through suppressing the anti-apoptotic activity of p21, and that a combined treatment TNF-α/Dox is an effective chemotherapeutic strategy for p53-deficient cancers.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Wei Cao, Wan-Hao Chi, Jun Wang, Juan-Juan Tang, Yan-Jun Lu,